INFI Key Statistics, Chart & Performance
The current stock price of INFI is 0.0447 USD. In the past month the price decreased by -49.26%. In the past year, price decreased by -96.66%.
INFI Technical Analysis
INFI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INFI. INFI has a bad profitability rating. Also its financial health evaluation is rather negative.
INFI Financial Highlights
Over the last trailing twelve months INFI reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 5.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INFI Forecast & Estimates
6 analysts have analysed INFI and the average price target is 0.31 USD. This implies a price increase of 584.56% is expected in the next year compared to the current price of 0.0447.
For the next year, analysts expect an EPS growth of 6.16% and a revenue growth 1.89% for INFI
INFI Ownership
INFI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INFI
Company Profile
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Company Info
INFINITY PHARMACEUTICALS INC
1100 Massachusetts Avenue, Floor 4
Cambridge MASSACHUSETTS 02138 US
CEO: Adelene Q. Perkins
Employees: 30
Phone: 16174531000.0
INFINITY PHARMACEUTICALS INC / INFI FAQ
What does INFI do?
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Can you provide the latest stock price for INFINITY PHARMACEUTICALS INC?
The current stock price of INFI is 0.0447 USD. The price decreased by -46.98% in the last trading session.
What is the dividend status of INFINITY PHARMACEUTICALS INC?
INFI does not pay a dividend.
What is the ChartMill technical and fundamental rating of INFI stock?
INFI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is INFINITY PHARMACEUTICALS INC (INFI) stock traded?
INFI stock is listed on the Nasdaq exchange.
Is INFINITY PHARMACEUTICALS INC (INFI) expected to grow?
The Revenue of INFINITY PHARMACEUTICALS INC (INFI) is expected to grow by 1.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for INFINITY PHARMACEUTICALS INC?
INFINITY PHARMACEUTICALS INC (INFI) will report earnings on 2023-11-13, after the market close.